Prior Myeloproliferative Neoplasm Associated with Poor Outlook for New Primary Cancers

Share this content:
Preceding myeloproliferative neoplasm is a predictor for poor outlook in patients who develop new primary cancers.
Preceding myeloproliferative neoplasm is a predictor for poor outlook in patients who develop new primary cancers.

Preceding myeloproliferative neoplasm is a predictor for poor outlook in patients who develop new primary cancers, a recent study published online ahead of print in the journal The Lancet Haematology has shown.

Previous research has demonstrated that patients with chronic myeloproliferative neoplasms, such as chronic myelogenous leukemia (CML) and primary myelofibrosis, are at an increased risk for developing new hematological or solid cancers.

Researchers sought to evaluate how preceding myeloproliferative neoplasms impact the prognosis of patients who develop a new primary cancer.

For the study, researchers analyzed data from 1,246 patients with a history of myeloproliferative neoplasms from population-based databases in Denmark from 1980 to 2011. Patients were compared to 5,155 subjects without a history of myeloproliferative neoplasm.

Results showed that among those with new localized solid tumors, the 5-year survival was 49.8% (95% CI: 39.1, 59.6), 47.9% (95% CI: 42.1, 53.4), and 48.0% (95% CI: 34.1, 60.7) for patients with preceding essential thrombocythemia, polycythemia vera, and chronic myeloid leukemia, respectively.

RELATED: Imatinib Safe, Effective in Treatment of Chronic Myeloid Leukemia

In matched patients without preceding myeloproliferative neoplasms, the 5-year survival rates were 72.4% (95% CI: 68.4, 76.0), 63.9% (95% CI: 61.5, 66.2), and 74.3% (95% CI: 68.2, 79.4), respectively.

Researchers found that patients with a preceding myeloproliferative neoplasm and a new solid tumor had a 1.21 to 2.28 times higher risk of death compared with those without myeloproliferative neoplasms.

Reference

  1. Frederiksen H, Farkas DK, Christiansen CF, et al. Survival of patients with chronic myeloproliferative neoplasms and new primary cancers: a population-based cohort study. The Lancet Haematol. 2015. [epub ahead of print]. doi: 10.1016/S2352-3026(15)00029-7.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs